About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)

Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
Biotech Stocks
It seems that the Biotech sector is now well into oversold territory and could very well see relative solid performance in 2022.

Biotech stocks have been hammered back to back for two years in a row now. The last time the SPDR ETF suffered a drop of 15% or more was in 2018, and the fund followed it up with a 33% increase in 2019. It dropped more than 15% in 2016 and followed that up with a 44% rise in 2017. With the recent massive sell-off in the biotech sector, it seems that sector is now well into oversold territory and could very well see relative solid performance in 2022.

Some notable biotech stocks include AbbVie Inc  (NYSE: ABBV), GH Research (NASDAQ: GHRS), Sundial Growers (NASDAQ: SNDL), Reata Pharmaceuticals (NASDAQ: RETA), Supernus Pharmaceuticals (NASDAQ: SUPN), Phibro Animal Health (NASDAQ: PAHC) and Cassava Sciences Inc (NASDAQ: SAVA).

One small-cap biotech stock that needs immediate attention is Lexston Life Sciences (OTC US:LEXTF). Some of the important points that make Lexston Life Sciences (OTCQB:LEXTF) a worthy candidate for discussion as per this Research report are as follows:

  1. The company’s Revolutionary Hybrid Business model is fueling organic growth from early revenue
  2. Newly DTC-Certified with a low float that could provide explosive moves on a daily basis when potential catalysts arise.
  3. Driven by Elite Management Team with years of experience successfully navigating Canada’s tough regulatory framework.
  4. Unrivaled Flexibility to Research and Develop new IP in Canada’s Rapidly-Growing Psy-che-delics industry.

5-meO-DM-T is often referred to as the “God Molecule,” for its ability to spark transcendental, transformative and religious experiences. Extracted from the Bufo alvarius toad from Mexico, it’s a powerful psy-che-delic believed to be effective in treating a variety of ailments like anxiety and depression. Click HERE to read more about a potential Canadian Biotech Disruptor Lexston Life Sciences (OTC US:LEXTF)

As per the research report, one of the most compelling arguments for Lexston Life Sciences comes from just looking at the company’s financials and stock structure. There are less than 60 million total shares, with the majority escrowed over the next three years. A full 20 million shares are presently restricted, limiting the maximum available float to just 36 million shares representing a cash total of less than $400,000 at today’s (1/6/22) prices. Even for a small and relatively new company, that’s a practically minuscule amount of available exposure for any publicly-traded company. If and when the company books more contracts and boosts its revenue, that could lead to a substantial and swift upward swing due to the limited float and extremely low share price (presently at $.01 on the OTCQB on 1/6/22).

Combined with the company’s already-steady revenues set to cover their expenses by the end of 2022, it’s a compelling argument to take a closer look at Lexston Life Sciences (OTCMKTS: LEXTF, CNSX: LEXT).

Source:

https://www.otcmarkets.com/stock/LEXTF/security

https://simplywall.st/stocks/ca/pharmaceuticals-biotech/cse-lext/lexston-life-sciences-shares

https://cbstockreports.com/unlocking-the-god-molecule/?utm_source=bullzeyemedia&utm_medium=affiliate&utm_campaign=lextf

Disclaimer: Please make sure to read and thoroughly understand our Disclaimer at WallStreetPR.com/Discliamer. We may be compensated for advertisement services on LEXTF by a third party.

Media Contact
Company Name: WallStreetPR
Contact Person: Ash K
Email: Send Email
Phone: 2019725655
Country: United States
Website: https://www.wallstreetpr.com/


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.